These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19337883)

  • 61. The dopamine theory of attention deficit hyperactivity disorder (ADHD).
    Levy F
    Aust N Z J Psychiatry; 1991 Jun; 25(2):277-83. PubMed ID: 1652243
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Scientific Evidence for the Evaluation of Neurological Soft Signs as Atypical Neurodevelopment Markers in Childhood Neuropsychiatric Disorders.
    D'Agati E; Pitzianti M; Curatolo P; Pasini A
    J Psychiatr Pract; 2018 Jul; 24(4):230-238. PubMed ID: 30427806
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Attention-deficit/hyperactivity disorder: a plausible mouse model?
    Granon S; Changeux JP
    Acta Paediatr; 2006 Jun; 95(6):645-9. PubMed ID: 16754543
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacotherapy for attention-deficit/hyperactivity disorder: from cells to circuits.
    Minzenberg MJ
    Neurotherapeutics; 2012 Jul; 9(3):610-21. PubMed ID: 22718077
    [TBL] [Abstract][Full Text] [Related]  

  • 65. ADHD: topic update.
    Bridge Denckla M
    Brain Dev; 2003 Sep; 25(6):383-9. PubMed ID: 12907270
    [No Abstract]   [Full Text] [Related]  

  • 66. [Use of drugs in attention deficit hyperactivity disorders].
    Guardiola A; Terra AR; Pereira KR; Rotta NT
    Arq Neuropsiquiatr; 1997 Sep; 55(3B):594-7. PubMed ID: 9629412
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Neurological soft signs, but not theory of mind and emotion recognition deficit distinguished children with ADHD from healthy control.
    Pitzianti M; Grelloni C; Casarelli L; D'Agati E; Spiridigliozzi S; Curatolo P; Pasini A
    Psychiatry Res; 2017 Oct; 256():96-101. PubMed ID: 28628794
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmaco fMRI: Determining the functional anatomy of the effects of medication.
    Wandschneider B; Koepp MJ
    Neuroimage Clin; 2016; 12():691-697. PubMed ID: 27766202
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research.
    Solanto MV
    Behav Brain Res; 2002 Mar; 130(1-2):65-71. PubMed ID: 11864719
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Recognizing minimal cerebral dysfunction in the infant and toddler. Some clinical clues and thoughts on management.
    Nichamin SJ
    Clin Pediatr (Phila); 1972 May; 11(5):255-7. PubMed ID: 5028568
    [No Abstract]   [Full Text] [Related]  

  • 71. Local brain gyrification as a marker of neurological soft signs in schizophrenia.
    Hirjak D; Kubera KM; Wolf RC; Thomann AK; Hell SK; Seidl U; Thomann PA
    Behav Brain Res; 2015 Oct; 292():19-25. PubMed ID: 26031380
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CDH2 mutation affecting N-cadherin function causes attention-deficit hyperactivity disorder in humans and mice.
    Halperin D; Stavsky A; Kadir R; Drabkin M; Wormser O; Yogev Y; Dolgin V; Proskorovski-Ohayon R; Perez Y; Nudelman H; Stoler O; Rotblat B; Lifschytz T; Lotan A; Meiri G; Gitler D; Birk OS
    Nat Commun; 2021 Oct; 12(1):6187. PubMed ID: 34702855
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Advances in the neurobiology of ADHD.
    Biederman J
    CNS Spectr; 2007 Apr; 12(4 Suppl 6):6-7. PubMed ID: 17717870
    [No Abstract]   [Full Text] [Related]  

  • 74. Attention deficit.
    Rosenberger PB
    Pediatr Neurol; 1991; 7(6):397-405. PubMed ID: 1797006
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Neurological and physiological bases of psychopathology.
    Reitan RM
    Annu Rev Psychol; 1976; 27():189-216. PubMed ID: 773261
    [No Abstract]   [Full Text] [Related]  

  • 76. Neurofeedback training in ADHD: more news on specificity.
    Brandeis D
    Clin Neurophysiol; 2011 May; 122(5):856-7. PubMed ID: 20833584
    [No Abstract]   [Full Text] [Related]  

  • 77. Moving towards causality in attention-deficit hyperactivity disorder: overview of neural and genetic mechanisms.
    Gallo EF; Posner J
    Lancet Psychiatry; 2016 Jun; 3(6):555-67. PubMed ID: 27183902
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Neural substrates underlying impulsivity.
    King JA; Tenney J; Rossi V; Colamussi L; Burdick S
    Ann N Y Acad Sci; 2003 Dec; 1008():160-9. PubMed ID: 14998882
    [TBL] [Abstract][Full Text] [Related]  

  • 79. EEG aspects in the diagnosis and treatment of minimal brain dysfunction.
    Satterfield JH; Lesser LI; Saul RE; Cantwell DP
    Ann N Y Acad Sci; 1973 Feb; 205():274-82. PubMed ID: 4511281
    [No Abstract]   [Full Text] [Related]  

  • 80. Usefulness of methylphenidate.
    Haddock ST
    N Engl J Med; 1972 Feb; 286(7):375. PubMed ID: 5008562
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.